Adaptimmune Therapeutics (ADAP) Set to Announce Quarterly Earnings on Wednesday

Adaptimmune Therapeutics (NASDAQ:ADAP) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 15th. Analysts expect Adaptimmune Therapeutics to post earnings of ($0.16) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative return on equity of 155.39% and a negative net margin of 188.90%. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $4.80 million. On average, analysts expect Adaptimmune Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP stock opened at $1.10 on Wednesday. The firm’s 50 day moving average price is $1.34 and its two-hundred day moving average price is $0.96. The stock has a market cap of $271.50 million, a PE ratio of -2.00 and a beta of 2.44. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.